论文部分内容阅读
目的观察西洛他唑治疗2型糖尿病下肢动脉病变的疗效及安全性。方法选择2型糖尿病下肢动脉病变患者52例,予西洛他唑100mgbid或阿司匹林100mgqn治疗12周,观察并检测两组治疗前后症状体征、患肢踝臂指数、血流量、血管直径及峰值血流速度、血生化等指标。结果治疗组间歇性跛行、疼痛症状改善率在80%以上;患肢踝臂指数增高明显(P<0.05);足背动脉血管直径、峰值流速、血流量治疗前后有显著差异(P<0.01),组间比较明显差异(P<0.05);肝肾功能等生化指标两组治疗前后无明显差异。结论西洛他唑对治疗2型糖尿病下肢动脉病变是一种安全有效的药物。
Objective To observe the efficacy and safety of cilostazol in the treatment of lower extremity arterial disease in type 2 diabetic patients. Methods 52 patients with type 2 diabetes mellitus with lower extremity arterial disease were treated with cilostazol 100mgbid or aspirin 100mgqn for 12 weeks. Symptoms and signs, limb ankle-brachial index, blood flow, vessel diameter and peak blood flow were observed and measured before and after treatment Speed, blood biochemical and other indicators. Results In the treatment group, the improvement rate of the intermittent claudication and pain symptom was over 80%; the ankle-brachial index of the limbs was significantly increased (P <0.05); there was a significant difference (P <0.01) between the dorsal artery diameter, peak velocity and blood flow before and after treatment (P <0.05). There was no significant difference in biochemical indexes such as liver and kidney function between the two groups before and after treatment. Conclusion Cilostazol is a safe and effective drug for the treatment of lower extremity arterial disease in type 2 diabetic patients.